Showing 1,221 - 1,240 results of 113,498 for search '(( 12 we decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 0.97s Refine Results
  1. 1221
  2. 1222

    Pannexin-1 hemichannel blockade by probenecid decreases dendritic morphology and process dynamics of retinal microglia. by Aurora M. Fontainhas (232472)

    Published 2011
    “…<p><b><i>A</i></b>. Microglial morphologic parameters of dendritic tree area, total dendritic length, and branch point number were significantly decreased by the application of probenecid (1mM), an antagonist of pannexin-1 hemichannels; (n = 46 cells). …”
  3. 1223
  4. 1224
  5. 1225
  6. 1226

    Positive modulation of mGluR5 decreases spine density in the nucleus accumbens but not in the dorsal striatum. by Kellie S. Gross (3115299)

    Published 2016
    “…<p>(A) Twenty-four hours after systemic administration, CDPPB (5–10 mg/kg, <i>n</i> = 18 animals) decreased dendritic spine density and frequency of small head diameter spines (0.2 μm bin) compared to vehicle control (<i>n</i> = 8) in the nucleus accumbens core. …”
  7. 1227
  8. 1228
  9. 1229
  10. 1230

    Image_5_v1_Systemic Immune Modulation Alters Local Bone Regeneration in a Delayed Treatment Composite Model of Non-Union Extremity Trauma.jpeg by Casey E. Vantucci (10528263)

    Published 2022
    “…This overall increase correlated with a decrease in bone volume (P = 0.057) at 6 weeks post-treatment and a significant decrease in mechanical strength at 12 weeks post-treatment compared to untreated rats. …”
  11. 1231

    Data_Sheet_1_Effect of decreased platelets on postoperative recurrence of chronic subdural hematoma.docx by Kenji Yagi (2990967)

    Published 2023
    “…CSDH recurred in 39 (8.5%) cerebral hemispheres. The recurrence rate was gradually increased in parallel with a decreasing PC. …”
  12. 1232

    Image1_Decreased mitochondrial respiration associates with frailty in community-dwelling older adults.jpg by Gianella Liabeuf (18512634)

    Published 2024
    “…<p>Aging population has led to an increased prevalence of chronic and degenerative pathologies. A manifestation of unhealthy aging is frailty, a geriatric syndrome that implies a non-specific state of greater vulnerability. …”
  13. 1233
  14. 1234
  15. 1235

    IUGR pups have decreased cell proliferation at age P14 compared to sham controls. by Camille M. Fung (844334)

    Published 2016
    “…IUGR decreased the number of Ki-67<sup>+</sup> cells at P14 only compared to shams (n = 5 for each treatment group, p = 0.04, representative micrographs from P14 mice are shown as the lower panel of A). …”
  16. 1236

    Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice by Michael T Buckley (37161)

    Published 2011
    “…All bladders were voided of urine prior to weighing. Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. , Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). , Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).…”
  17. 1237
  18. 1238
  19. 1239

    Reduction of SIRT1 during DNA damage decreases the number of silent clones that have methylation. by Heather M. O'Hagan (271283)

    Published 2008
    “…One representative bisulfite sequenced clone is presented for each HSVTK silent clone. (B) A dot plot of the mean number of CpGs methylated per HSVTK silenced clone from either un-siRNA treated cells (untreated) (<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000155#pgen-1000155-g005" target="_blank">Figure 5D & E</a>), non-target siRNA treated cells (NT), or SIRT1 siRNA treated cells (SIRT1). …”
  20. 1240

    Decreased Variability of the 6-Minute Walk Test by Heart Rate Correction in Patients with Neuromuscular Disease by Kira P. Prahm (670305)

    Published 2014
    “…</p><p>Conclusion</p><p>A modified 6-minute walk test, by correcting walking distance with average heart rate during walking, decreases the variability among repeated 6-minute walk tests, and should be considered as an alternative outcome measure to the standard 6-minute walk test in future clinical follow-up and treatment trials.…”